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Expression of Cyclooxygenase-1 and -2 in Normal and
Glaucomatous Human Eyes
Christian Maiho¨fner,1,2 Ursula Schlo¨tzer-Schrehardt,2,3 Hans Gu¨hring,1
Hanns Ulrich Zeilhofer,1 Gottfried O. H. Naumann,3 Andreas Pahl,1 Christian Mardin,3
Ernst R. Tamm,4 and Kay Brune1
PURPOSE. Primary open-angle glaucoma (POAG) is the predom-
inant form of chronic glaucoma, but the underlying pathologic
mechanisms are largely unknown. Because prostaglandins
(PGs) have been introduced into POAG treatment with remark-
able success, this study was undertaken to investigate whether
a change in the expression of the PG-synthesizing enzymes
cyclooxygenase (COX)-1 and -2 might be involved in the patho-
genesis of POAG.
METHODS. Expression of COX-1 and -2 was assessed by confocal
laser microscopy, immunohistochemistry, Western blot analy-
sis, and real-time RT-PCR in human eyes with different forms of
glaucoma (primary open-angle, angle-closure, congenital juve-
nile, and steroid-induced), as well as in age-matched control
eyes. Additionally, PGE2 was measured in aqueous humor by
means of an enzyme-linked immunoassay as a product of COX
activity.
RESULTS. In normal eyes, ocular COX-1 and -2 expression were
largely confined to the nonpigmented secretory epithelium of
the ciliary body. By immunohistochemistry and real-time RT-
PCR, COX-2 expression was completely lost in the nonpig-
mented secretory epithelium of the ciliary body of eyes with
end-stage POAG, whereas COX-1 expression was unchanged.
By immunohistochemistry, in the ciliary bodies of eyes in five
patients with diagnosis of early POAG, eyes in two had com-
plete loss of COX-2 expression and in three showed only a few
remaining scattered COX-2–expressing cells. COX-2 expres-
sion in the ciliary body was also lost in patients with steroid-
induced glaucoma and was reduced in patients receiving top-
ical steroid treatment. Eyes of patients with either congenital
juvenile or angle-closure glaucoma showed COX-2 expression
indistinguishable from control eyes. Aqueous humor of eyes
with POAG contained significantly less PGE2 than control eyes.
CONCLUSIONS. Both cyclooxygenase isoforms are constitutively
expressed in the normal human eye. Specific loss of COX-2
expression in the nonpigmented secretory epithelium of the
ciliary body appears to be linked to the occurrence of POAG
and steroid-induced glaucoma. (Invest Ophthalmol Vis Sci.
2001;42:2616–2624)
Primary open-angle glaucoma (POAG) is among the domi-nating ocular diseases in industrialized countries.1,2 In-
traocular pressure (IOP) increases in persons older than 50
years without any subjective symptoms until irreversible dam-
age occurs.1,2 If untreated, it leads to impaired vision and
ultimately to blindness in approximately 2% of the elderly
population.1,2 The pathogenesis of POAG is still largely un-
known, although in some patients there is evidence of genetic
linkage to GLC1A/B.3–5
POAG shares several characteristics with corticosteroid hor-
mone–induced secondary open-angle glaucoma. Prolonged
topical administration of glucocorticoids to the eye causes
increased IOP and a decay of vision in about 30% of the
patients.6,7 Glucocorticoids are well known to inhibit the ex-
pression of cyclooxygenase (COX)-2, a key enzyme in the
formation of prostaglandins (PGs).8 These agents play an im-
portant role in the regulation of IOP.9 Therefore, reduction of
PGs in the eye by inhibition of COX-2 expression appears to be
a mechanism by which glucocorticoids cause secondary glau-
coma. In fact, synthetic PGF2a analogues such as latanoprost
are remarkably effective in glaucoma therapy.9–11
PG production involves two isoenzymes, COX-1 and -2.12–14
Today, it is generally assumed that COX-1 is constitutively
expressed in most tissues and displays the characteristics of a
“housekeeping” enzyme.14 By contrast, COX-2 is the product
of an immediate early gene that is rapidly inducible and tightly
regulated.12,13 Under normal conditions, COX-2 expression is
highly restricted to certain organs including the central ner-
vous system (CNS)15,16 and the kidney,17 but COX-2 expres-
sion can be dramatically increased in various tissues after ini-
tiation of transcription by activating factors including different
proinflammatory cytokines,18 sheer forces in the arterial
wall,19 or salt deprivation.17
In view of the potential importance of cyclooxygenases in
glaucoma, the localization and expression of these enzymes in
normal and glaucomatous human eyes was investigated.
MATERIALS AND METHODS
Informed consent to eye and tissue donation was obtained and the
study adhered to the tenets of the Declaration of Helsinki.
Immunofluorescence and Confocal
Laser Microscopy
Anterior segments prepared from normal human donor eyes were
embedded in optimal cutting temperature compound (OCT; Tissue-
Tek; Miles Laboratories, Elkhart, IN) and snap frozen in isopentane-
liquid nitrogen. Six-micrometer cryostat sections were thawed onto
gelatin-coated glass slides, air dried, and fixed in paraformaldehyde
(4%, 10 minutes) followed by incubation in Tris-buffered saline (TBS;
pH 7.4) containing 10% normal donkey serum and 1% bovine serum
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albumin (BSA) for 60 minutes at room temperature (RT). After the
slides were rinsed in TBS, incubation was continued with the poly-
clonal goat anti-human COX-1 or -2 antiserum (dilution, 1:1000; Santa
Cruz Biotechnology, Santa Cruz, CA) in TBS containing 1% BSA over-
night at 4°C. After slides were again rinsed with TBS, binding sites
were detected using donkey anti-goat IgG conjugated with cyanine-3
(diluted 1:200 in TBS, for 1 hour at RT; Santa Cruz Biotechnology).
Sections were coverslipped with TBS-glycerol (1:1, pH 8.6) and exam-
ined by confocal laser scanning microscopy (MRC 1000; Bio-Rad,
Richmond, CA).
Electron Microscopic Immunohistochemistry
Tissue specimens of normal human donor eyes were fixed in a solution
of paraformaldehyde (4%) and glutaraldehyde (0.1%) in 0.1 M cacody-
late buffer (pH 7.4; 1–2 hours at 4°C). After specimens were rinsed,
they were dehydrated serially to 70% ethanol at 220°C, embedded in
resin (LR White; Electron Microscopy Sciences, Fort Washington, PA),
and polymerized for 24 hours at 45°C. Ultrathin sections were incu-
bated successively in drops of TBS, 0.5% ovalbumin and 0.5% fish
gelatin in TBS, anti-human COX-2 antibody (diluted 1:300 in TBS-
ovalbumin overnight at 4°C), and 10 nm gold-conjugated secondary
antibody (diluted 1:30 in TBS-ovalbumin; for 1 hour at RT; BioCell,
Cardiff, UK). After a rinse, sections were stained with uranyl acetate
and examined with an electron microscope (EM 906; Leo,
Oberkochen, Germany).
Protein Extraction and Western Blot Analysis
Ciliary processes from normal donor eyes (,4 hours after death) were
homogenized in lysis buffer, containing 0.15 M NaCl, 0.1 M TBS, 50
mM diethyldithiopyrocarbonate, 1% (vol/vol) Tween-20, and 10 mM
phenylmethylsulfonyl fluoride. For Western blot analysis, protein (50
mg/lane) was loaded on a 10% SDS-polyacrylamide gel and electroblot-
ted onto nitrocellulose membranes (Schleicher and Schuell, Dassel,
Germany). Membranes were probed with polyclonal goat anti-human
COX-2 antiserum (diluted 1:1000), followed by a horseradish peroxi-
dase (HRP)–linked donkey anti-goat IgG secondary antibody (diluted
1:1000; Santa Cruz Biotechnology). Blots were developed with en-
hanced chemiluminescence (ECL) detection reagents (Amersham, Ar-
lington Heights, IL) and exposed to film for 2 to 10 minutes.
RT-PCR Analysis
RNA was prepared using a kit (RNeasy; Qiagen, Hilden, Germany) from
the ciliary processes of normal human donor eyes, which were ho-
mogenized with a Dounce homogenizer (Bellco Glass Co., Vineland,
NJ) in lysis buffer (RLT; Qiagen).
For real-time RT-PCR, the following primers and probes were se-
lected. For COX-2 (accession number M90100): 59-CACAATCTGGCT-
GAGGGAACA-39 (upstream) and 59-ACTGGTATTTCATCTGCCTGC-
TCT-39 (downstream), 59-(FAM)CCTGCCAGCAA (TAMRA)TTTGCCTG-
GTGAAT-39 (internal oligonucleotide probe). Human b-actin (acces-
sion number M12481) was used for quantification, and the following
primers and probes were used: 59-TCACCCACACTGTGCCCATCTA-
CGA-39 (upstream), 59-GGATGCCACAGGATTCCATACCCA-39 (down-
stream), and 59-(FAM)TATGCTC(TAMRA)TCCCTCACGCCATCCTGC-
GT-39 (internal oligonucleotide probe).
PCR reagents were purchased from Perkin Elmer-Applied Biosys-
tems (Weiterstadt, Germany), primers and probes from TIB Molbiol
(Berlin, Germany), and rTth-DNA-polymerase from Diagonal (Mu¨nster-
Roxel, Germany). The PCR mixture (25 ml total volume) consisted of
200 nM primer, 100 nM probe, 300 nM dNTPs, 3 mM Mn(OAc)2, 1 ml
total RNA, 0.02 U rTth-DNA polymerase, and 53 Taq buffer (TaqMan
EZ; containing 250 mM Bicine buffer, 575 mM potassium acetate, 0.05
mM EDTA, 40% [wt/vol] glycerol [pH 8.2]; Perkin Elmer-Applied Bio-
systems). Amplification and detection were performed with a se-
quence detection system (Prism 7700; Perkin Elmer-Applied Biosys-
tems) with the following profile: 50°C for 2 minutes, 60°C for 30
minutes, and 95° for 5 minutes and 45 cycles of 94°C for 15 seconds
and 60°C for 1 minute. Quantification was performed by determining
the threshold cycle (CT). CT is proportional to the amplified starting
copy number of cDNA or RNA.20 All reactions were controlled by
standards (no-template control and standard positive control). The
quantity of mRNA was calculated by normalizing the CT of genes of
interest to the CT of the housekeeping protein b-actin of the same RNA
probe, according to the following formula: DCT 5 CT
COX-2 mRNA 2
C T
b-actinmRNA.
RNA Isolation and RT-PCR Analysis from
Paraffin-Embedded Tissue
To investigate COX-2-mRNA expression in glaucomatous eyes, total-
RNA was isolated from paraffin-embedded eye sections fixed with 4%
paraformaldehyde (fixation time, ,12 hours). Ten-micrometer-thick
slices of respective eyes were cut. Afterward, ciliary processes were
separated by means of microdissection and transferred into cups (Ep-
pendorf, Fremont, CA). All isolation steps were performed at room
temperature in the same cup. First, paraffin was dissolved in Roticlear
(Carl Roth GmbH, Karlsruhe, Germany). The solution was then centri-
fuged at full speed for 5 minutes, and the supernatant was removed.
This procedure was followed by three intensive washing steps with
ethanol (96%) to remove the Roticlear agent. After the last wash,
ethanol was totally removed and the pellet was air dried. All steps were
performed in detail, according to the manufacturer’s protocol (Mini
RNeasy; Qiagen) Protocol. After adding 350 ml of lysis buffer, the tissue
samples were shredded with a microshredder.
For RT-PCR, 1 mg eye tissue RNA was reverse transcribed into
cDNA (Superscript II Polymerase; Life Technologies GmbH, Eggen-
stein, Germany). Special primers were designed for the detection of
potential fragmented RNA, according to reports in the respective
literature.21,22 In particular, they should amplify very short target
sequences. The sequences of the oligonucleotide primers (Eurogentec,
Liege, Belgium) were COX-1 (79 bp): 59-CAC AGT GCG CTC CAA CCT
TA-39 (upstream), 59-TGG AGA AAG ACT CCC AGC TGA-39 (down-
stream), and 59-(FAM) CTT ATC CCC AGT CCC CCC ACC TAC AAC TC
(TAMRA)-39 (internal oligonucleotide probe); COX-2 (88 bp): 59-GCT
GGA ACA TGG AAT TAC CCA-39 (upstream), 59-CTT TCT GTA CTG
CGG GTG GAA-39 (downstream), and 59-(FAM) CCT GCC AGC AA
(TAMRA) T TTG CCT GGT GAAT-39 (internal oligonucleotide probe);
and b-actin (79 bp): 59-AGT ACT CCG TGT GGA TCG GC-39 (up-
stream), 59-GCT GAT CCA CAT CTG CTG GA-39 (downstream). PCR
was conducted in a real-time thermal cycler (ABI 7700; Perkin Elmer-
Applied Biosystems) using a kit (AmpliTaq Gold; Perkin Elmer-Applied
Biosystems).
Light Microscopic Immunohistochemistry
Immunohistochemistry was performed on paraffin-embedded eye sec-
tions from the archives of the Department of Ophthalmology of the
University of Erlangen-Nu¨rnberg and on donor eyes from the Glaucoma
Research Foundation (San Francisco, CA), both fixed with 4% para-
formaldehyde. The labeled streptavidin-biotin method performed with
a kit (LSAB Plus; Dako, Glostrup, Denmark) was applied according to
the manufacturer’s instructions. Briefly, after endogenous peroxidase
activity of the tissue was quenched with 3% hydrogen peroxide in
distilled water for 5 minutes, sections were incubated with proteinase
K (0.02 mg/ml in TBS; pH 8) for 20 minutes for antigen unmasking.
After sections were rinsed, they were incubated with a polyclonal goat
anti-human COX-1 or -2 antibody (diluted 1:100 in TBS), with the
biotinylated link antibody and the HRP-conjugated streptavidin, respec-
tively, for 30 minutes each. 3-Amino 9-ethyl carbazole (10 minutes;
Dako) was used as a chromogenic substrate. The sections were coun-
terstained with Mayer’s hemalun (Chroma, Ko¨ngen, Germany) and
mounted (Aquatex; Merck, Darmstadt, Germany). After staining pro-
cedures, sections were coded and assessed by blinded observers (CM,
USS) for presence of COX-1 and -2 immunoreactivity (IR).
Negative controls included incubation of ocular tissues with non-
immunized goat serum, omitting the primary antibody, and incubation
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of negative control tissues (muscle). Positive tissue controls included
sections of brain, kidney, and uterus (data not shown).
Measurements of PGE2 in Aqueous Humor
Aqueous humor obtained at eye surgery was immediately snap frozen
in liquid nitrogen. PGE2 concentrations were determined using a com-
mercially available enzyme immunoassay kit (Cayman Chemicals, Ann
Arbor, MI). The reliable limit of quantification for PGE2 was 15 pg/ml,
and the coefficient of variation was less than 14% within the calibration
range (15–1000 pg/ml).
RESULTS
Expression of COX-1 and -2 in Normal
Human Eyes
The expression of COX-1 and -2 at different sites in the human
eye was investigated with immunofluorescence and confocal
laser microscopy (Fig. 1). In eight apparently normal eyes of
human organ donors (no known ocular diseases; age range,
38–85 years), which were enucleated shortly after death (,8
hours) COX-1 and -2 IR were most prominent in the cells of the
nonpigmented epithelial layer of the ciliary body (Figs. 1A, 1B,
1E). By contrast, only minor expression of both cyclooxygen-
ases was observed in other areas of the anterior eye segments.
Some COX-2 IR was observed in connective tissue cells scat-
tered in the iris stroma (Fig. 1C), particularly in the pupillary
and iris root area, as well as in some stromal cells between the
ciliary muscle and the anterior chamber (Fig. 1D).
The ultrastructural localization of COX-2 was revealed by
immunoelectron microscopy. The strongest staining was found
in the basolateral membranes of the nonpigmented secretory
epithelial cells (Fig. 2A), which secret the eye’s aqueous hu-
mor. Additionally, COX-2-protein was found in association with
intercellular contacts (maculae and zonulae adherentes, Figs.
2B, 2C), and in the rough endoplasmic reticulum including the
perinuclear cistern (Fig. 2D). By contrast, no COX-2 IR was
detected in the pigmented epithelial layer of the ciliary body. A
schematic overview of the distribution of COX-2 in the ciliary
epithelium based on immunoelectron microscopy is shown in
Figure 2E.
Constitutive expression of COX-2-protein was further con-
firmed by Western blot analysis using protein extracts from
human ciliary body tissue. The antibody raised against human
COX-2 protein detected a double band of approximately 68 to
75 kDa, corresponding to the molecular weight of COX-2 (Fig.
3). The detected bands were also in the same range as a
parallel-run positive control.
Expression of COX-1 and -2
in Glaucomatous Eyes
Paraffin-embedded sections of surgically enucleated blind and
painful glaucomatous eyes were obtained from the archives of
the Department of Ophthalmology at the University of Erlan-
gen, Germany. Five eyes with absolute (end-stage) POAG (72 6
6 years), five with secondary angle-closure glaucoma due to
rubeosis iridis (78 6 7 years), and three with congenital juve-
FIGURE 1. Indirect immunofluores-
cence and confocal laser scanning
microscopy for COX-1 and -2 protein
in normal human donor eyes. (A)
COX-2 IR (bright red) was constitu-
tively found in the epithelium of the
ciliary body of normal human donor
eyes. (B) Differential expression of
COX-2 in the two layers of the ciliary
epithelium. COX-2 protein stained in-
tensely in the secretory nonpig-
mented epithelial layer (filled arrow)
in contrast to the lightly stained pig-
mented epithelial layer (open ar-
row). The ciliary body could be seen
below the epithelial layers. (C)
COX-2 IR in connective tissue cells of
the iris stroma (arrow). (D) Stromal
cells located in the ciliary connective
tissue between the ciliary muscle and
the posterior chamber showing
COX-2 IR (arrows). (E) Localization
of COX-1 IR in the nonpigmented
epithelial layer of the ciliary body
(filled arrow). The pigmented epi-
thelial layer showed no COX-1 IR
(open arrow). Scale bar, (A) 250 mm;
(B, E) 25 mm; (C, D) 50 mm.
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nile glaucoma (44 6 2 years) were analyzed. In the end-stage
POAG eyes, COX-2 expression was completely lost in the
nonpigmented epithelium of the ciliary body (Figs. 4C, 4D).
This loss was very specific in two respects. First, loss of COX-2
expression was restricted to the nonpigmented ciliary epithe-
lium and did not affect COX-2 expression in the connective
tissue cells of the ciliary body and iris stroma (4D, inset).
Second, COX-1 expression remained unchanged, both in the
ciliary body and in other sites of ocular COX-1 expression (Figs.
4J, 4K). By contrast, all eyes with congenital juvenile and
angle-closure glaucoma exhibited an expression of COX-2 very
similar to that in normal control eyes (Figs. 4F, 4G).
Equally processed and age-matched normal human eyes
obtained from organ donors and eyes enucleated for small
juxtapapillary malignant melanomas of the choroid not affect-
ing anterior segment tissues served as control eyes (Figs. 4A,
4B). The latter eyes are regarded as otherwise normal and have
the advantage of a very short time until fixation of the tissue
can begin. Therefore, postmortem changes can be largely ex-
cluded. These eyes showed the same COX-2 expression as
observed in normal human donor eyes.
Because glucocorticoids are known to inhibit COX-2 ex-
pression in various cell types,8,14,16 we investigated whether
topical ocular steroid treatment affects the COX-2 expression
in the ciliary epithelium. Four paraffin-embedded eyes were
examined from patients (75 6 12 years) who had been treated
topically with glucocorticoids preceding perforation in ulcer-
ative herpetic keratitis. COX-2 expression was almost com-
pletely absent in glucocorticoid-treated eyes (Fig. 4H). Because
the analysis was performed on paraffin-embedded sections
from the archives of the Department of Ophthalmology at the
University of Erlangen, the specimens were not suitable for
quantitative investigations, such as Western blot analysis or
RT-PCR.
To investigate COX-2 expression in earlier stages of POAG,
eyes were obtained from the Glaucoma Research Eye Donor
Network (GREDN) of the Glaucoma Research Foundation
(time from death to dissection ,8 hours). Patients with clini-
cally diagnosed glaucoma in various stages of the disease were
registered in their lifetimes by the foundation. All donors
agreed that at death their eyes could be immediately enucle-
ated and committed to glaucoma research. After evaluation of
the clinical data, five eyes (80.5 6 4 years) with earlier stages
of POAG were found. All patients had typical glaucomatous
visual field loss: one had already undergone glaucoma filtration
surgery 2 years before his death. The cup-to-disc ratio ranged
between 0.7 and 0.95. In addition, we had access to two eyes
with ocular hypertension without any clinical signs of glau-
coma and one eye with steroid-induced glaucoma. Of the five
eyes of patients with POAG, two were completely devoid of
COX-2 IR, and three still showed a few scattered COX-2–
positive cells in the ciliary epithelium (Fig. 4E). COX-2-protein
FIGURE 2. Electron microscopic im-
munogold labeling for COX-2 protein
in the ciliary epithelium of normal
human donor eyes. (A) A strong im-
munogold reaction for COX-2 was lo-
calized to the basolateral membranes
of the nonpigmented secretory epi-
thelial cells (arrow). (B) Association
of gold labeling for COX-2 with inter-
cellular contacts between cells of the
nonpigmented epithelial layer (filled
arrow) and between cells of the non-
pigmented epithelial layer and the
pigmented epithelial layer (open ar-
row). (C) Presence of gold labeling
indicating COX-2 protein along a
macula adherens type of intercellular
contact (arrow). (D) Localization of
COX-2 protein in the perinuclear cis-
tern (filled arrow) and rough endo-
plasmic reticulum (open arrow). (E)
Overview of the ultrastructural distri-
bution of COX-2 protein (stars) in the two epithelial layers of the ciliary body. The anatomic regions shown in (A) through (D) are indicated. npe,
nonpigmented epithelial layer; pe, pigmented epithelial layer; n, nucleus; rer, rough endoplasmic reticulum; pc, perinuclear cistern. Scale bar, (A)
1 mm; (B) 0.8 mm; (C) 0.2 mm; (D) 0.5 mm.
FIGURE 3. Western blot analysis demonstrating the expression of
COX-2 protein in the ciliary body of normal human donor eyes. Lane
1: Total cell lysates prepared from ciliary body tissue (50 mg protein);
lane 2: purified COX-1 (0.1 mg); and lane 3: purified COX-2 protein
(0.1 mg) were electrophoresed, transferred onto nitrocellulose mem-
brane, and immunostained with polyclonal antiserum against human
COX-2. The antibody used was highly specific for COX-2 and did not
detect COX-1. Unpurified COX-2 proteins derived from cell lysates or
tissues typically produced a double or triple band in Western blot
analysis at 68 to 75 kDa (lane 1). Similar results were obtained in three
independent experiments.
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was completely absent in the eye with steroid-induced glau-
coma (Fig. 4J).
To add further proof to our histologic and biochemical
findings (described later), we tried to assess the expression of
COX-2 mRNA in paraffin-embedded tissue specimens. We had
access to two specimens obtained during eye surgery that were
FIGURE 4. Light micrographs of im-
munohistochemistry for COX-2 pro-
tein on paraffin-embedded eye sec-
tions. Positive cells show reddish-
brown staining (in contrast to the
black melanin pigment of the pig-
mented epithelial layer of the ciliary
body). (A) Control eye enucleated
for a small juxtapapillary malignant
melanoma of the choroid not affect-
ing anterior segment tissues. (B)
Higher magnification of section in
(A) shows intense staining of the
nonpigmented epithelial layer of the
ciliary body (arrow). COX-2–positive
cells were also found in the connec-
tive tissue between the ciliary body
and the posterior chamber (inset).
The staining pattern exactly corre-
sponded to the distribution of COX-2
IR in Figures 1A, 1B, and 1C. (C)
Ciliary body of an eye with absolute
POAG. (D) Higher magnification of
section in (C) shows absence of
COX-2 IR in the nonpigmented epi-
thelial layer (arrow). COX-2–positive
cells were still found in the connec-
tive tissue between the ciliary body
and the posterior chamber (inset).
Cell nuclei are stained blue. (E) Eye
with an early form of POAG. IOP was
elevated (24 mm Hg) and there were
visual field defects. COX-2 IR was
clearly reduced compared with con-
trol eyes but was still detectable in
some cells of the nonpigmented cili-
ary epithelium (arrow). (F, G) Ap-
proximately normal content of
COX-2 IR in ciliary epithelia of eyes
with congenital juvenile (F) and sec-
ondary angle-closure (G) glaucoma.
(H) Ciliary body of an eye pretreated
with glucocorticoids showed mark-
edly decreased content of COX-2
protein (arrow) compared with the
control in (A). (I) Eye with steroid-
induced glaucoma (IOP, 25 mm Hg).
COX-2 IR was completely absent in
this eye. (J) Section of control eye
shown in (A) and (B) stained for
COX-1 protein showed intense stain-
ing of the nonpigmented epithelial
layer of the ciliary body (arrow). (K)
Eye with absolute POAG shown in
(C) and (D) stained for COX-1 pro-
tein. In sharp contrast to COX-2 IR,
no change in COX-1 IR was detected
(arrow) compared with the control
eye (J). npe, nonpigmented epithe-
lial layer; pe, pigmented epithelial
layer. Original magnification, (A, C,
F–H) 355; (B, D, E, J, K) 3140; (B,
D, inset) 3200; (I) 3150.
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carefully prepared with the intention of using them for the
analysis of mRNA expression. As far as possible, the specimens
were processed in RNase-free conditions after enucleation of
the eye. Because the specimens were fixed in paraformalde-
hyde and degradation of RNA could be expected, we designed
special primers for the detection of small fragments (COX-1, 79
bp; COX-2, 88 bp; b-actin, 67 bp), according to reports in the
literature.21,22 The fragments were supposed to be within the
approximately 200 nucleotide fragments resulting from fixa-
tion. One eye with absolute (end-stage) POAG (from an 80-
year-old woman) was compared with an eye enucleated due to
a small juxtapapillary malignant melanoma (from a 70-year-old
man), which served as a control. The respective ciliary pro-
cesses were separated by microdissection, and afterward, RNA-
extraction was performed. As seen in Figure 5B, the control
eye showed a clear expression of COX-2 mRNA. In contrast, no
COX-2 mRNA was detectable in the eye enucleated due to
absolute POAG. No difference in b-actin and COX-1 content
was observed between both eyes (Fig. 5A).
PGE2 Concentrations in Aqueous Humor
PGE2 content was analyzed in the ocular aqueous humor in
patients with different ocular diseases (Fig. 6). PGE2 concen-
trations were significantly less in patients with POAG (34.3 6
17.6 ng/ml [SEM]; n 5 19) than in control patients (48.9 6 7.6
ng/ml; n 5 13) who underwent eye surgery for cataract (P ,
0.02; ANOVA followed by the Bonferroni post hoc test), but
comparable with patients who received topical steroids
(25.5 6 2.5 ng/ml; n 5 3) for treatment of anterior uveitis or
FIGURE 5. Real-time RT-PCR experi-
ments comparing the expression of
mRNA for COX isoforms in ciliary
bodies of an eye enucleated due to
absolute POAG and a small juxtapap-
illary malignant melanoma, respec-
tively. (A) Original amplification plot
for COX-1 mRNA. A prominent fluo-
rescence signal was obtained from
lipopolysaccharide (LPS) stimulated
human monocytes (pink). Basal
COX-1 mRNA expression was found
in both eyes: control eye (orange);
POAG (green); no-template control
(blue). Inset: electrophoresis of the
specimens after real-time RT-PCR for
b-actin (top) and COX-1 (bottom).
Lane 1: control eye; lane 2: POAG;
lane 3: human monocytes; and lane
4: no-template control. The obtained
bands were of the expected 79-bp
(COX-1) and 67-bp (b-actin) sizes.
(B) Original amplification plot for
COX-2 mRNA. A prominent fluores-
cence signal was obtained from LPS-
stimulated human monocytes (pink).
Basal COX-2 mRNA expression was
found in the eye with malignant mel-
anoma (orange). In contrast, COX-2
mRNA was not detectable in the eye
with POAG (green); no-template con-
trol (blue). After amplification, the
specimens were electrophoresed to
assess the size of the respective frag-
ments (inset). Lane 1: amplification
product of eye with malignant mela-
noma of the expected 88-bp size;
lane 2: no signal detectable in the
eye with POAG; lane 3: signal ob-
tained from LPS-stimulated human
monocytes of the expected size; and
lane 4: no amplification for no-tem-
plate control.
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corneal herpes virus infection. PGF2a content in the same
samples was comparatively low (,4 pg/ml) and showed no
significant differences between patients with POAG and cata-
ract (data not shown).
DISCUSSION
Reduced COX-2-Expression in POAG
This study demonstrated a complete and selective loss of
COX-2 expression in the ciliary nonpigmented epithelial layer
of eyes with end-stage POAG. This loss was anatomically highly
selective. The changes in COX-2 expression were restricted to
the secretory epithelium of the ciliary body, whereas COX-2
expression remained unchanged in other parts of the eye.
COX-1 expression was unchanged throughout the eye. The
loss of COX-2 expression appears to be associated with POAG
and is not a consequence of increased IOP, in that COX-2 was
present in normal amounts in eyes with congenital juvenile and
angle-closure glaucoma that had long-standing elevations of
IOP. Furthermore, COX-2 expression was already clearly re-
duced at earlier stages of POAG development (compare Fig.
4E). Two of five eyes with early stages of POAG showed
complete COX-2 loss, and three of five eyes showed COX-2 IR
only in some scattered cells. Therefore, the selective loss of
ciliary COX-2 expression appears to be linked to the occur-
rence of POAG. Although the results obtained from our spec-
imens were very consistent, further investigations are needed
to elucidate whether reduced COX-2 expression is a common
characteristic of POAG or occurs only in a particular subtype of
this disease.
In addition, this study showed that COX-2 expression in the
ciliary epithelium was lost in steroid-induced glaucoma and
was reduced in patients treated topically with glucocorticoids.
Moreover, aqueous humor of eyes treated topically with glu-
cocorticoids contained significantly less PGE2 than did control
eyes.
The proposed mechanism of corticosteroid-induced glau-
coma includes morphologic and functional changes in the
trabecular meshwork system. These changes are thought to be
similar to those in POAG.6 In particular, trabecular cells of
human eyes treated with glucocorticoids show endoreplica-
tion of nuclei,23 an increase in cell size,23 and excessive pro-
duction of an approximately 56-kDa glycoprotein, termed tra-
becular meshwork glucocorticoid response protein (TIGR) and
transcribed by the GLC1A gene.24–27 This may indicate that
loss of COX-2 expression is secondary to changes in the tra-
becular meshwork system, because COX-2 expression is nor-
mal in other parts of the eye. Furthermore, the outflow resis-
tance is markedly increased in eyes with POAG and steroid-
induced glaucoma.28–35 Because PGs are known to facilitate
outflow,9,10,36–38 the reduction of PGs in aqueous humor, as
reported in this study, may contribute to the increased outflow
resistance in POAG and steroid-induced glaucoma.
PGE2 Concentration in the Aqueous Humor
in POAG
The PGE2 concentration in the aqueous humor of glaucoma-
tous eyes was found to be significantly lower than in control
eyes. The decrease in endogenous PGs may contribute to the
elevation of IOP in the glaucomatous eyes. This is consistent
with the utility of PG derivatives in the treatment of POAG. For
example, PGF2a analogues have been introduced into the ther-
apy of POAG with remarkable success.10,11,39,40
PGF2a is thought to influence uveoscleral outflow through
interaction with PGF receptors.28 These receptors are located
in proximity to the localization of COX-1 and -2 described in
this study.41–43 In addition, at least part of the effects of PGF2a
occur through PGF2a-induced PGE2 release.
44 This PG has
been shown to decrease IOP, as well.36–38 It is not known
which of the various PGs is the most relevant in the human
eye. However, the predominant prostanoid receptor in the
human ciliary body is EP3.36 Stimulation of this receptor seems
to be more important for reduction of IOP than stimulation of
the FP receptor.36 This is consistent with our observation that
the PGE2 content of the aqueous humor in human eyes ex-
ceeded that of PGF2a several times.
PGE2 concentrations in aqueous humor of patients with
POAG showed considerable interindividual variation, although
overall the data demonstrate significantly lower concentrations
of PGE2 in POAG. The PG-concentration in the ocular fluid is
the sum of all COX-activity in anterior eye segments. We
suggest there would be a more dramatic reduction of PGE2 if
PG production in the ciliary epithelium alone could be mea-
sured.
Nevertheless, our PG measurements agree with our immu-
nohistochemical and molecular biological data and provide
supportive evidence for a decreased COX-2-expression in
POAG.
Constitutive Expression of COX-1 and -2 in the
Human Eye
This is the first study that describes a constitutive expression of
both COX isoforms in the anterior segments of normal human
eyes. Neufeld et al.45 have investigated the expression of COX
isoforms in the human optic nerve head of normal and glau-
comatous eyes. They found no basal COX-2 expression in the
optic nerve and only a slight increase of COX-2 IR in POAG. It
was argued that COX-2-derived PGs might play a role in the
pathogenesis of glaucomatous optic neuropathy. In the ante-
rior segments of the eye, the ability of the ciliary epithelium
and the ciliary body to produce PGs has been previously
described.36,46 Yousufzai et al.44 reported that release of PGE2
is inhibited by dexamethasone in a dose-dependent manner.
FIGURE 6. Measurement of PGE2 in the aqueous humor of patients
with various ocular diseases. PGE2 was determined by enzyme-linked
immunoassay. (E) PGE2 levels in individual patients. Straight line:
median level; shaded area: 25% to 75% range. PGE2 concentrations of
the ocular aqueous humor of eyes of patients with POAG or of patients
pretreated with glucocorticoids were significantly lower than in the
aqueous humor of eyes of control patients with cataract. *P , 0.05;
**P , 0.02.
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They suggested that this inhibition may be due to inhibition of
phospholipase A2. However, inhibition of phospholipase A2 by
glucocorticoids occurs only at very high dosages.47 An alterna-
tive and more likely mechanism is the hormonal regulation of
constitutively expressed COX-2.12,14,16 The glucocorticoid-de-
pendent COX-2 expression, and therefore PG production, may
comprise a mechanism by which IOP is regulated under phys-
iological conditions. Circadian oscillations of endogenous glu-
cocorticoid plasma levels may well contribute to the circadian
rhythm of IOP.
In addition, ocular COX-2 expression appears to be regu-
lated by glucocorticoids. Our findings further extend the con-
cept14 that COX-2 contributes constitutively to the physiolog-
ical regulation in highly differentiated organ systems such as
the central nervous system (CNS),15,16 the kidney,17 and, now,
the eye. One explanation for this finding may be that the eye
ontogenetically originates from the neuroepithelium and
shares many characteristics with the CNS.
It is at present not known what factors lead to the observed
decrease in COX-2 expression in POAG. These patients are not
generally without COX-2, for the absence of expression is
confined to the ciliary epithelium of the eye (e.g., stromal cells
in the ciliary body and iris of eyes with POAG exhibit normal
COX-2 IR). This specific loss may be explained either by the
existence of COX-2 inductors specific for the ciliary body or by
a failure within the ciliary epithelium. It is interesting to note
that the TIGR gene, in which several gene mutations have been
reported in familial forms of POAG,3,5 is located in close prox-
imity to the human COX-2 gene. The TIGR gene has been
mapped to chromosomal region 1q24.3-q25.2.48 Tay et al.49
assigned the human COX-2 gene to 1q25. Furthermore, pro-
motors of both genes have glucocorticoid response elements.
Thus, the COX-2 and TIGR genes share similarities regarding
regulation of expression. Interactions of both genes and their
products may be possible, although chromosomal linkage of
two different genes does not necessarily imply any interac-
tions.
The implications of decreased COX-2 expression are un-
known. In particular, it remains unclear whether decreased
COX-2 expression contributes to the increased IOP in POAG or
is just an epiphenomenon of the pathogenesis of POAG. Unlike
most other organ systems, the eye has no PG-metabolizing
enzymes. PGs are removed from the aqueous humor by a
specific transporter.50,51 Therefore, PGs derived from the non-
pigmented ciliary epithelial layer could interact with cells of
the ciliary body or trabecular meshwork, releasing metallopro-
teinases.52–54 These enzymes are known to degrade proteins of
the extracellular matrix and thereby facilitate uveoscleral or
trabecular meshwork outflow.52–54 This mode of PG action is
thought to contribute to the IOP-decreasing effect of PGs.
Lower levels of PGs in aqueous humor as reported in this study
may then give rise over time to an increased outflow resistance.
In summary, this study reports for the first time that both
COX isoforms are constitutively expressed in anterior seg-
ments of normal human eyes. Unlike in congenital juvenile or
angle-closure glaucoma, COX-2 expression was strongly re-
duced or abolished in the ciliary epithelium of eyes with POAG
and steroid-induced glaucoma. Therefore, this study may pro-
vide new insights in the pathogenesis of POAG. The functional
implications of reduced COX-2 expression will be the subject
of future investigations.
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